FDA Approves First New Sunscreen Ingredient in Over 20 Years
The FDA approved bemotrizinol as a new sunscreen active ingredient, marking the first addition to the approved list since the late 1990s. Bemotrizinol provides protection against both UVA and UVB rays while demonstrating low systemic absorption through the skin. This approval could expand consumer options and potentially improve sun protection formulations available in the market.
The Food and Drug Administration approved bemotrizinol as a permitted sunscreen active ingredient on Tuesday, ending a more than 20-year gap since the last new ingredient was added to the approved list. According to FDA documentation, bemotrizinol offers protection against both ultraviolet A and B rays while maintaining low levels of absorption into the body through the skin, addressing previous safety concerns that have slowed sunscreen ingredient approvals. This approval represents a significant development in dermatological sun protection, as the sunscreen market has remained largely stagnant in terms of active ingredient innovation. The addition of bemotrizinol could lead to new formulation options for manufacturers and potentially improved efficacy or tolerability for consumers. The extended timeline between approvals reflects the FDA's rigorous safety evaluation process for topical ingredients.
What's missing
Coverage does not detail what specific advantages bemotrizinol offers over existing approved ingredients (zinc oxide, titanium dioxide, avobenzone, etc.) or the timeline for when products containing it will reach consumers. Additionally, the reasons why no new ingredients were approved for over 20 years—whether due to safety concerns, regulatory barriers, or lack of industry innovation—are not explained.
How coverage differed
The Hill's coverage is straightforward and factual, presenting the approval as a notable regulatory milestone without editorial commentary. Different sources may emphasize either the consumer benefits angle or the regulatory/scientific significance, but the core facts of the approval and ingredient properties remain consistent across credible reporting.
What different sources said
- The HillCenter
FDA approves first new sunscreen ingredient in more than 20 years
Related
Consumer Reports Releases 2025 Sunscreen Recommendations After Testing 51 Products
Consumer Reports lab-tested 51 sunscreens and released its top recommendations for 2025, with Coppertone Water Babies lotion SPF 50 ranking as the best overall option. The testing evaluated both chemical and mineral sunscreens, with lotion formulations preferred over sprays due to better visibility of application amounts. The findings emphasize year-round sunscreen use and proper application techniques to maximize UV protection.
AZD0120: Dual-Targeting CAR-T Therapy Shows Promise in Preclinical Multiple Myeloma Studies
AstraZeneca's AZD0120, a dual-targeting CAR-T cell therapy, demonstrated potent efficacy against multiple myeloma in preclinical laboratory and animal models. The therapy targets both BCMA and CD19 antigens and uses a faster manufacturing process called FasTCAR designed to reduce production time and improve cell quality. The results support advancing the treatment to clinical trials, potentially offering patients a more accessible and effective option for multiple myeloma treatment.
U.S. Drug Shortages Decline but Duration Lengthens, Analysis Shows
The number of prescription drug shortages in the U.S. fell 23% last year to the lowest level since 2017, according to a new analysis by U.S. Pharmacopeia. However, the average duration of shortages increased to 5.3 years in 2025, up from 4.3 years in 2024, with nearly two-thirds of out-of-stock medicines unavailable for more than three years. The findings suggest that while the frequency of shortages is improving, the persistence of individual shortages remains a significant systemic problem affecting patients across multiple therapeutic categories.